BAYER AG

Explore Bayer AG’s recent stock drop, legal risks, and new FDA‑accelerated therapy for menopausal hot flashes and EMA‑orphan retinal drug—what it means for investors.

Missouri jury weighs Roundup design‑defect claims; Bayer’s €7 bn settlement and EPA’s new review may reshape glyphosate liability and investor confidence.

Discover how Bayer’s €375 M sale of Stivarga to Grünenthal reshapes oncology, boosts financial health, and taps price‑based reimbursement trends.

Kerendia gets FDA approval for type‑1 diabetes‑related CKD, offering the first new treatment in 30 years and boosting Bayer’s renal portfolio.

Explore Bayer AG’s hybrid governance, glyphosate litigation risks, and new oncology approval—insights to sharpen investor strategy and forecast growth.

Explore Bayer AG’s latest moves: litigation risks, Apollo partnership, and mixed quarterly results—all shaping investor sentiment and debt reduction plans.

Discover how Bayer AG’s new debt‑reduction and capital‑injection strategy boosts R&D, mitigates litigation risks, and strengthens its global pharma position.

Explore Bayer’s $7.25 billion Roundup settlement and how court scrutiny may reshape its future strategy and shareholder value.

Explore Bayer AG’s bold strategy: a national “Science Delivers” tour, FDA‑approved Hyrnuo for HER2‑NSCLC, and 14,000‑job cuts that reshape its future.

Discover how Bayer’s new tyrosine‑kinase drug HYRNUO and its winterrapé bio‑fuel partnership accelerate cancer care and low‑carbon energy—boosting health, sustainability, and shareholder value.